palmitoylethanolamide.com.au
HomeResearchIndraccolo 2022

Looking for Responders among Women with Chronic Pelvic Pain Treated with a Comicronized Formulation of Micronized Palmitoylethanolamide and Polydatin

Indraccolo U, Favilli A, Dell'Anna A, Di Francesco A, Dionisi B, Giugliano E, Murina F, Stocco E. Biomed Res Int. 2022;2022:8620077.

Meta-analysisHumansWith polydatin

This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Meta-analysis
Subjects
Individual patient data from the published studies of women with chronic pelvic pain, dyspareunia, dysuria, dyschezia or dysmenorrhoea treated with the combination
Dose used in the study
Micronised palmitoylethanolamide with polydatin, short courses
Duration
3-month follow-up
What was measured
Conditional probability of a good response (pain score down 3 or more), poor response or no response, by baseline variables.

What the authors reported

More than half of women were good responders. Women with a baseline pain score above 6 were the most likely to respond, whatever the underlying condition.

Limits of this study

The authors note that only short-course combination data could be assessed and that concerns about the literature remain; they wrote the paper to help plan a randomised trial. A responder analysis cannot show effect without a control group. Authors declare no conflicts.

Source

PubMed 35578721 · doi:10.1155/2022/8620077

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.